在急性心肌梗塞的玻尿酸纤维解药疗法
J Llevadot1, R P Giugliano, E M Antman
1TIMI Study Group, 333 Longwood Ave, Suite 402, Boston, MA 02115, USA.
JAMA
|July 31, 2001
概括
新的玻尿酸纤维溶解药物,如丁氏甲和丁氏甲,为急性心肌梗塞提供了方便的管理. 它们的疗效和安全性与组织类型等离子体激活剂 (tPA) 相当,这表明它们在再注射治疗中起着关键作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血栓形成的管理
背景情况:
- 来自人类组织类型等离子体激活剂 (tPA) 的新玻尿酸纤维化剂正在出现,用于治疗急性心肌梗塞中闭塞性血栓.
- 这些药物旨在更有效,更方便地溶解血栓.
研究的目的:
- 审查新型玻尿酸纤维溶解药物: reteplase,lanoteplase 和 tenecteplase. 这三种新型玻尿酸纤维溶解药物有哪些?
- 评估它们的药理动力学,药理动力学和临床结果.
主要方法:
- 在MEDLINE,EMBASE和当前内容数据库 (1983-2001) 中进行了搜索.
- 包括药理动力学,药理动力学研究,以及 reteplase,lanoteplase 和 tenecteplase 的临床结果.
- 分析了138篇确定文章中的38篇,通过同行评审的出版物或会议演示来评估数据质量.
主要成果:
- 甲和甲的疗效和安全性与加速输液复合tPA相美,由于玻尿酸注射的便利性增加.
- 拉诺特普拉斯与肝素结合,显示与tPA相似的死亡率,但内出血的发病率明显较高.
结论:
- 玻尿酸纤维溶解剂的使用提供了显著的便利性.
- 鉴于可比于加速输液复合tPA的结果,玻尿酸纤维化剂可能是急性心肌梗塞现代再输血策略的组成部分.
相关概念视频
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...